Isodiol International Inc. Announces Extension of Licensing Agreement With Kathy Ireland and Level Brands

Terms of License Agreement extended to 10 years, Territory expanded to worldwide

January 22, 2018 – Vancouver, BC – Isodiol International Inc., (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has signed an amendment to the license agreement with Level Brands Inc. (NYSE American: LEVB).  The amended agreement extends the terms from five years to ten years and expands the territorial coverage from North America to worldwide.  The amendment was entered into after both parties concluded discussions contemplated under the terms of the agreement.

Marcos Agramont, CEO of Isodiol said, “Upon further discussion with Kathy Ireland and the Level Brands team, it became clear that both sides share a common goal, which is to help people around the globe understand how cannabidiol is beneficial for the human body.   With this expanded agreement, we will now be able to introduce a variety of Isodiol brands to Kathy’s extremely large network around the globe.  Overall, Level Brands is innovative in licensing, marketing and brand management and this will further assist Isodiol in providing consistent and highly bioactive products.   The opportunity to increase this partnership from North America to worldwide is something that we believe will have a tremendous impact on Isodiol in the short and long term.”

Kathy Ireland, Chairman Emeritus and Chief Brand Strategist of Level Brands said, “Our vision is that Isodiol will become the leading CBD company in the world. The CBD market is at its infancy, and we believe, based on our research and decades of brand building, that the CBD industry will see enormous growth over the next decade on a worldwide basis. We look forward to working with the Isodiol team to execute on a multi-faceted marketing strategy that we feel will enable Isodiol to grow its bulk and private label businesses, as well be able to rapidly go to market with specialized branded lines of unique and best in class products.”

The Isodiol product portfolio will include body balms, tinctures, personal care, nano-mist, and functional beverages.

Martin Sumichrast, Chairman and CEO of Level Brands also added, “We believe that the technology that the Isodiol team has acquired and is acquiring will allow Isodiol to be at the forefront of the CBD industry. Our companies have embarked on a decade long partnership which has the potential to not only sell consumer branded products worldwide, but also bring to market new innovative means I believe will provide consumers the benefits of CBD. We are incredibly grateful for this opportunity and the leadership that Kathy and the team at kathy ireland® Worldwide has and will provide to Level Brands and the team at Isodiol.”

No additional consideration was issued for the expanded territorial coverage from North America to worldwide.

About Isodiol International Inc. (

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.

About Level Brands, Inc. (

Level Brands creates bold, unconventional and socially responsible branding for leading businesses. With a focus on corporate brand management and consumer products marketing art, beauty, fashion, health & wellness including the beverage space, entertainment, and real estate. Licensed brand marketing is at the core of the Level Brand businesses: Ireland Men One or I’M1, for millennial men and the women who love them; Encore Endeavor One or EE1, corporate brand management and producer of experiential entertainment events and products across multiple platforms; kathy ireland® Health & Wellness; Beauty & Pin-Ups, Level Brands’ hair care and disruptive women’s products brand.


“Marcos Agramont” CEO & Director


BeTru Organics
C3 Global Biosciences

Join Us On Facebook:
Twitter: @isodiol


Carrie Booze
North 6th Agency
212-334-9753 ext.142

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.